Centre's cancer drug margin cap draws mixed response from industry, groups
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓The NPPA set a 30% trade margin cap on 137 cancer drugs, effective November 9, 2026.
- ✓While the pharma industry welcomed the move to help optimise pricing, patient groups worry about actual affordability.
- ✓Abhay Soi said, “Regulation should consider overall healthcare economics rather than merely the difference between procurement price and MRP.”
Story at a Glance
- Category
- BUSINESS
- Reported By
- Business Standard
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
The NPPA's 30% trade margin cap on 137 oncology drugs, effective November 9, has drawn support from the pharma industry, while patient groups question its impact on affordability.
The Centre's decision to cap trade margins on 137 cancer drugs at 30% has raised questions over its impact on treatment costs and medicine affordability.
Sanket Koul New Delhi
Listen to This Article
The Centre’s plan to cap trade margins for 137 cancer drugs has prompted divergent views among the industry and patient advocacy groups on the extent to which the move could benefit patients.
The National Pharmaceutical Pricing Authority (NPPA) had last week finalised a margin cap at 30 per cent of the maximum retail price (MRP) for oncology drugs, corresponding to a mark-up of 42.86 per cent on the price to stockist/price to distributor (PTS/PTD). The new MRPs are set to come into effect from November 9, 2026.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Business Standard
Read the full, original unfiltered story directly on the publisher's portal.